Senju, Bausch settle eye drop litigation against Indian generics maker

Senju Pharmaceutical and Bausch Health have reached an “amicable settlement” to its patent suit against Aurobindo over generic Prolensa (bromfenac) eye drops, court filings confirm.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Americas

Bausch Health resolves IBS patent litigation

7 May 2020 Canada-based Bausch Health has agreed to settle its dispute with generic maker Sandoz over the latter’s attempt to release a generic version of antibiotic Xifaxan.

Americas

Pharma unit could get green light to launch IBS generic

2 August 2022 Dispute centres on Xifaxan, used to treat irritable bowel syndrome | ‘Significant hurdle’ cleared in bringing drug to market | Bausch wins partial victory after Alvogen subsidiary failed to show that patent claims were obvious.

More on this story

Americas

Bausch Health resolves IBS patent litigation

7 May 2020 Canada-based Bausch Health has agreed to settle its dispute with generic maker Sandoz over the latter’s attempt to release a generic version of antibiotic Xifaxan.

Americas

Pharma unit could get green light to launch IBS generic

More on this story

Americas

Bausch Health resolves IBS patent litigation

7 May 2020 Canada-based Bausch Health has agreed to settle its dispute with generic maker Sandoz over the latter’s attempt to release a generic version of antibiotic Xifaxan.

Americas

Pharma unit could get green light to launch IBS generic